BCL2L1 and neoplasm: Unfortunately, tumor cells can become resistant to these therapies, allowing them to efflux chemotherapeutic agents, modify drug targets by altering expression of genes and proteins involved in carcinogenesis, and increase production of anti-apoptotic proteins such as Bcl-2 and Bcl-Xl [121].